Drug Trial Radar · NCT07058025
Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants
Last checked: Nov 19, 2026Latest source record: Jul 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
168
Planned (sponsor's estimate)
Start
Oct 1, 2025
Primary completion
Sep 30, 2028
Study completion Sep 30, 2038
Sponsor
- Lead sponsor
- Ottawa Hospital Research InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR); Stem Cell Network
- First posted
- Jul 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 4 days, up to 14 days
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial aims to evaluate the safety and efficacy of mesenchymal stromal cell (MSC) therapy in extreme preterm infants to prevent bronchopulmonary dysplasia, the main respiratory complication of preterm birth. Study participants will receive either multiple intravenous doses (total of 3 doses) of MSC derived from human donor umbilical cord tissue (intervention group) or no uc-MSC injection (control group) to confirm the safety of IV MSC in extreme preterm infants and evaluate the potential benefit of MSC therapy on their respiratory health as well as on other complications related to preterm birth.
Conditions
- Bronchopulmonary Dysplasia (BPD)
- ELGAN (22-28SA)
Interventions
Human Allogenic Umbilical Cord Mesenchymal Stromal CellsBiological
IV administration of uc-MSC every 7 days ± 1 day for 3 weeks. Randomized double blinded
Sham procedure controlOther
Sham procedure (mimic IV catheter insertion adn cell product infusion behing a screen). Repeated weekly for 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of mechanical ventilation-free days accounting for mortalityTime frame: 120 days
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Royal Alexandra Hospital/Stollery Children's Hospital
Edmonton, Alberta, Canada
McMaster Children's Hospital
Hamilton, Ontario, Canada
The Ottawa Hospital
Ottawa, Ontario, Canada
Sunnybrook Health Sciences Ctr
Toronto, Ontario, Canada
Mount Sinai Hospital
Toronto, Ontario, Canada
CHU Sainte-Justine
Montreal, Quebec, Canada
McGill Montreal Children's Hospital
Montreal, Quebec, Canada
Université Laval
Québec, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.